ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. BeOne Medicines's annualizedNet Income for the quarter that ended in Mar. 2026 was MXN16,399 Mil.
BeOne Medicines's average Total Assets over the quarter that ended in Mar. 2026 was MXN150,843 Mil. Therefore, BeOne Medicines's annualized ROA % for the quarter that ended in Mar. 2026 was 10.87%.
The historical rank and industry rank for BeOne Medicines's ROA % or its related term are showing as below:
MEX:BGNEN'
s ROA % Range Over the Past 10 Years
Min: -49.13 Med: -23.75 Max: 7.02
Current: 7.02
During the past 13 years, BeOne Medicines's highest ROA % was 7.02%. The lowest was -49.13%. And the median was -23.75%.
MEX:BGNEN's ROA % is ranked better than 90.16% of 1423
companies
in the Biotechnology industry
Industry Median: -32.9
vs MEX:BGNEN: 7.02
BeOne Medicines (MEX:BGNEN) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
BeOne Medicines ROA % Related Terms
BeOne Medicines ROA % Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BeOne Medicines's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's ROA % distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
BeOne Medicines (MEX:BGNEN) has a ROA % of 10.87% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on BeOne Medicines and its competitors. According to the industry distribution chart, BeOne Medicines ranks #140 out of 1423 companies in the Biotechnology industry, placing it in the top 9.8%.
Is BeOne Medicines' ROA % too high?
BeOne Medicines' current ROA % is 10.87%. Based on the distribution chart, BeOne Medicines ranks #140 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BeOne Medicines has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' ROA % compare to RVMD and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #140 out of 1423 companies for ROA %. This places BeOne Medicines in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current ROA % is 10.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
BeOne Medicines (MEX:BGNEN) has a current ROA % of 10.87%. The stock's GF Value™ is MXN3,774.03, compared to a current price of MXN2,858.16 — trading 24.3% below its estimated fair value. The current ROA % is 10.87%. BeOne Medicines' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For BeOne Medicines (MEX:BGNEN), the current ROA % is 10.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (MEX:BGNEN) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of MXN2,858.16 is trading 24.3% below its estimated GF Value™ of MXN3,774.03.
Key valuation signals for MEX:BGNEN:
ROA %: 10.87%
GF Value™: MXN3,774.03 vs. price of MXN2,858.16 (24.3% below fair value)
No single metric tells the full story. See the MEX:BGNEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score
Get the complete analysis for MEX:BGNEN
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BGNEN has been successfully added to your 
